ACAD Share Price

Open 39.00 Change Price %
High 39.63 1 Day -0.06 -0.15
Low 38.79 1 Week -0.08 -0.20
Close 39.14 1 Month 8.77 28.88
Volume 1213887 1 Year 19.95 103.96
52 Week High 42.29
52 Week Low 17.02
ACAD Important Levels
Resistance 2 39.92
Resistance 1 39.60
Pivot 39.19
Support 1 38.68
Support 2 38.36
NASDAQ USA Most Active Stocks
CTRP 47.59 1.13%
ADBE 119.47 -0.13%
FSLR 33.57 -8.33%
FSLR 33.57 -8.33%
CERN 55.37 0.18%
BIDU 186.01 0.21%
AAPL 137.11 0.30%
AAPL 137.11 0.30%
FB 136.12 1.79%
MASI 87.05 2.03%
More..
NASDAQ USA Top Gainers Stocks
VALV 0.05 66.67%
LOCM 0.09 50.00%
BASI 1.33 31.68%
WRES 0.09 28.57%
INAP 2.31 27.62%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
SKBI 0.10 25.00%
AETI 2.40 23.08%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
LLEN 0.01 -50.00%
LIWA 0.01 -50.00%
QTWW 0.08 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
More..

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD)

ACAD Technical Analysis 5
As on 22nd Feb 2017 ACAD Share Price closed @ 39.14 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 31.42 & Strong Buy for SHORT-TERM with Stoploss of 31.73 we also expect STOCK to react on Following IMPORTANT LEVELS.
ACAD Target for February
1st Target up-side 38.03
2nd Target up-side 40.45
3rd Target up-side 42.86
1st Target down-side 31.15
2nd Target down-side 28.73
3rd Target down-side 26.32
ACAD Other Details
Segment EQ
Market Capital 128332624.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.acadia-pharm.com
ACAD Address
ACAD
11085 Torreyana Road
Suite 100
San Diego, CA 92121
United States
Phone: 858-558-2871
Fax: 858-558-2872
Interactive Technical Analysis Chart ACADIA Pharmaceuticals Inc. ( ACAD NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on ACADIA Pharmaceuticals Inc.
ACAD Business Profile
ACADIA Pharmaceuticals Inc., incorporated in 1993, is a biopharmaceutical company focused on small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. The Company has four product candidates in clinical development led by pimavanserin. It holds worldwide commercialization rights to pimavanserin. In addition, the Company has a product candidate in Phase II development for chronic pains and a product candidate in Phase I development for glaucoma. The Company's clinical-stage product candidates include Pimavanserin, Alpha Adrenergic Agonists, Muscarinic Agonist and AM-831. The Company used its drug discovery platform to discover additional product candidates. These include two preclinical programs that provide the potential for disease-modifying therapies for treating Parkinson’s disease and other neurological disorders. Corporate Headquarters of the Company is at 11085 Torreyana Road, Ste. 100, San Diego, CA 92121-1104.